Zai Lab Pty. Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2015
NCT02397005
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Zai Biopharmaceutical (Suzhou) Co., Ltd. | Zai Lab | Zai Lab (Hong Kong), Ltd. | Zai Lab Pty. Ltd. | Zai Lab (Shanghai) Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Eczema (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Hypersensitivity (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 1)

Liver Neoplasms (Phase 2)

Lung Diseases, Obstructive (Phase 1)

Lung Neoplasms (Phase 3)

Melanoma (Phase 1)

Ovarian Neoplasms (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Pulmonary Fibrosis (Phase 1)

Small Cell Lung Carcinoma (Phase 3)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial APIs: 37